Skip to main content
PMC home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1988 Aug;26(2):183–186. doi: 10.1111/j.1365-2125.1988.tb03385.x

Excretion of tiapamil in breast milk.

D Hartmann 1, N O Lunell 1, G Friedrich 1, A Rane 1
PMCID: PMC1386526  PMID: 3207555

Abstract

The excretion of tiapamil in breast milk was studied in six lactating mothers (3-7 days post partum) following a single oral 600 mg dose of the drug. The milk/plasma ratio of tiapamil derived from the areas under the plasma and milk concentration-time curves was 0.44 +/- 0.10 mean +/- s.d.). Assuming an intake of 350 ml of milk during a dosing interval of 12 h, the newborn would be exposed at the maximum to 0.053 mg tiapamil. This small amount does not represent a risk for the baby.

Full text

PDF
186

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Andersen H. J. Excretion of verapamil in human milk. Eur J Clin Pharmacol. 1983;25(2):279–280. doi: 10.1007/BF00543804. [DOI] [PubMed] [Google Scholar]
  2. Anderson P., Bondesson U., Mattiasson I., Johansson B. W. Verapamil and norverapamil in plasma and breast milk during breast feeding. Eur J Clin Pharmacol. 1987;31(5):625–627. doi: 10.1007/BF00606644. [DOI] [PubMed] [Google Scholar]
  3. Balansard P., Elkik F., Levenson J. A., Ciampi M., Sans P. Effect of a new calcium antagonist, tiapamil, in hypertension of the elderly. Br J Clin Pharmacol. 1984 Dec;18(6):823–829. doi: 10.1111/j.1365-2125.1984.tb02551.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Eigenmann R., Blaber L., Nakamura K., Thorens S., Haeusler G. Tiapamil, a new calcium antagonist. 1. Demonstration of calcium antagonistic activity and related studies. Arzneimittelforschung. 1981;31(9):1393–1401. [PubMed] [Google Scholar]
  5. Eigenmann R., Gerold M., Hefti F., Jovanovic D., Haeusler G. Tiapamil, a new calcium antagonist. 2. Further pharmacological characterization and toxicology. Arzneimittelforschung. 1981;31(9):1401–1410. [PubMed] [Google Scholar]
  6. Findlay J. W. The distribution of some commonly used drugs in human breast milk. Drug Metab Rev. 1983;14(4):653–684. doi: 10.3109/03602538308991403. [DOI] [PubMed] [Google Scholar]
  7. Fleishaker J. C., Desai N., McNamara P. J. Factors affecting the milk-to-plasma drug concentration ratio in lactating women: physical interactions with protein and fat. J Pharm Sci. 1987 Mar;76(3):189–193. doi: 10.1002/jps.2600760302. [DOI] [PubMed] [Google Scholar]
  8. Heizmann P., Wendt G., Von Alten R., Zinapold K., Buser C. Determination of tiapamil and of its two main metabolites in plasma and in urine by high-performance liquid chromatography. J Chromatogr. 1984 Sep 14;310(1):119–127. doi: 10.1016/0378-4347(84)80073-0. [DOI] [PubMed] [Google Scholar]
  9. Hinderling P. H., Eckert M., Gasic S., Eichler H. G., Pötzi R., Heizmann P. Comparative pharmacokinetics and cardiovascular effects of tiapamil in healthy volunteers and patients with hepatic cirrhosis. Eur J Clin Pharmacol. 1986;31(4):397–404. doi: 10.1007/BF00613513. [DOI] [PubMed] [Google Scholar]
  10. Miller M. R., Withers R., Bhamra R., Holt D. W. Verapamil and breast-feeding. Eur J Clin Pharmacol. 1986;30(1):125–126. doi: 10.1007/BF00614209. [DOI] [PubMed] [Google Scholar]
  11. Ramuz H. A new Ca++ antagonist, Ro 11-1781, and its metabolites. Synthesis and physicochemical properties. Arzneimittelforschung. 1978;28(11):2048–2051. [PubMed] [Google Scholar]
  12. Rhomberg F., Bachmann K., Bächtold H., Müller P. Erste Erfahrungen mit dem Calcium-Antagonisten Tiapamil in der Behandlung der arteriellen Hypertonie. Schweiz Med Wochenschr. 1983 Dec 10;113(49):1845–1846. [PubMed] [Google Scholar]
  13. Salorinne Y., Himberg J. J., Eskelinen E. Long-term tiapamil treatment of patients with angina pectoris. Clin Cardiol. 1983 Apr;6(4):171–175. doi: 10.1002/clc.4960060404. [DOI] [PubMed] [Google Scholar]
  14. Spencer S. A., Hull D. Fat content of expressed breast milk: a case for quality control. Br Med J (Clin Res Ed) 1981 Jan 10;282(6258):99–100. doi: 10.1136/bmj.282.6258.99. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Syversen G. B., Ratkje S. K. Drug distribution within human milk phases. J Pharm Sci. 1985 Oct;74(10):1071–1074. doi: 10.1002/jps.2600741010. [DOI] [PubMed] [Google Scholar]
  16. Wendt G. Pharmacokinetics and metabolism of tiapamil. Cardiology. 1982;69 (Suppl):68–78. doi: 10.1159/000173539. [DOI] [PubMed] [Google Scholar]
  17. Whitehead R. G., Paul A. A. Infant growth and human milk requirements. A fresh approach. Lancet. 1981 Jul 25;2(8239):161–163. doi: 10.1016/s0140-6736(81)90352-4. [DOI] [PubMed] [Google Scholar]
  18. Wilson J. T., Brown R. D., Hinson J. L., Dailey J. W. Pharmacokinetic pitfalls in the estimation of the breast milk/plasma ratio for drugs. Annu Rev Pharmacol Toxicol. 1985;25:667–689. doi: 10.1146/annurev.pa.25.040185.003315. [DOI] [PubMed] [Google Scholar]
  19. Wilson J. T. Determinants and consequences of drug excretion in breast milk. Drug Metab Rev. 1983;14(4):619–652. doi: 10.3109/03602538308991402. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES